Open AccessPrognostic Impact of Serum Growth Differentiation Factor 15 Level in Acute Myeloid Leukemia Patients
Author(s) -
Hany M. Hegab,
Amro Mohamed Sedky El-Ghammaz,
Mostafa El Razzaz,
R. Helal
Publication year - 2020
Publication title -
indian journal of hematology and blood transfusion/indian journal of hematology and blood transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.213
H-Index - 15
eISSN - 0974-0449
pISSN - 0971-4502
DOI - 10.1007/s12288-020-01315-7
Subject(s) - gdf15 , medicine , myeloid leukemia , hematology , gastroenterology , multivariate analysis , pathophysiology , bone marrow , cancer , leukemia , oncology
Growth differentiation factor 15 (GDF15) plays an important role in cancer pathophysiology and prognosis. However, limited studies analyzed its level and prognostic value in acute myeloid leukemia (AML) patients. This study included 56 adult AML patients. Serum GDF15 level was measured at diagnosis in all patients by enzyme-linked immunosorbent assay. Remission and survival statuses were assessed at 90 days following treatment. GDF15 level was significantly higher in patients than in controls ( P < 0.001). GDF15 level correlated positively with age ( P < 0.001), hemoglobin level ( P = 0.027), and platelet count ( P = 0.024). High GDF15 above the median level was associated with inferior OS ( P = 0.044) together with high platelet count ( P = 0.006) and high bone marrow blast percent ( P = 0.038). There was no statistically significant difference between patients with GDF15 above and below the median level regarding DFS (P = 0.881). On multivariate analysis for OS, GDF15 level was an independent risk factor ( P = 0.047). In conclusion, serum GDF15 level is significantly elevated in AML patients and high GDF15 level is associated with inferior OS.